MedTrace Logo

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

NCT07262970 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-12-04

No results posted yet for this study

Summary

This expanded access program is intended to provide ersodetug, an investigational drug, to eligible participants who suffer from inadequately controlled hypoglycemia due to tumor-associated hyperinsulinism and are unable to participate in ersodetug clinical trial. Participation is open to participants who meet the eligibility criteria and for whom access to the investigational drug is deemed appropriate by the treating physician.

Conditions

  • Tumor-associated Hyperinsulinism (Tumor HI)

Interventions

DRUG

Ersodetug (9 mg/kg) + SOC

Open-Label Participants with a diagnosis of Tumor HI (insulin- or IGF-producing tumors)

Sponsors & Collaborators

  • Rezolute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07262970 on ClinicalTrials.gov